Big Data- Epidemiology of Antimicrobial Resistance

需要使用效果较差或毒性相对较弱的备用抗生素（氨基糖苷类、替加环素和粘菌素/多粘菌素B）的共同耐药可能使生存恶化。我们使用美国医院的大型临床数据库调查了革兰氏阴性血流感染（gnbsi）中难以治疗的耐药（DTR），这种感染的定义是对所有一线药物(碳青霉烯类、β -内酰胺类和氟喹诺酮类药物（FQ）缺乏敏感性。我们发现，耐药GNBSI患者的生存高度取决于是否存在积极的一线选择；DTR限制了治疗选择的储备药物，包括氨基糖苷类，这远远不是普遍有效的。在GNBSI中，DTR仍然不常见（1%），但在接受检查的一半医院和所有美国地区都有发生。这项工作已在美国传染病学会和重症医学学会年会上发表。

Co-resistance necessitating use of less effective or relatively toxic reserve antibiotics (aminoglycosides, tigecycline and colistin/polymyxin B) may worsen survival. We investigated difficult-to-treat resistance (DTR) in gram-negative bloodstream infections (GNBSIs) defined by absence of susceptibility to all first-line agents (carbapenems, beta-lactams and fluoroquinolones (FQ) using a large clinical database of US hospitals. We found that survival in antimicrobial-resistant GNBSI is highly contingent on presence of active first-line option(s); DTR limits treatment options to reserve agents, including aminoglycosides, which are far from universally active. DTR remained infrequent (1%) among GNBSI, but occurred at half of the hospitals examined and across all US regions. This work has been presented at the Annual Meetings of the Infectious Diseases Society of America and Society of Critical Care Medicine. We went on to validate our findings using the Cerner Health facts repository of electronic health records. As part of the NIH Antimicrobial Resistance Outcomes Research Initiative (NIH-ARORI), we also went on to study the landscape of emerging antibiotics to understand their real-world use and demand. We found that ceftazidime-avibactam use increased several fold replacing colistin use, however overall use was still modest. As part of an FDA-funded initiative, we determined that treatment opportunities for difficult-to-treat antibiotic resistant pathogens in US hospitals remains small, suggesting that non-revenue based strategies might be necessary to sustain antibiotic development. As part of ongoing work, we are performing national extrapolations to understand recent trends in difficult-to-treat resistance, conducting an analysis of burden and impact of inappropriate antibiotic therapy in bacteremia and sepsis. As part of the NIH Antimicrobial Resistance Outcomes Research Initiative (NIH-ARORI), we determined that one in every five patients with bloodstream infection in US hospitals receives empiric antibiotic therapy that is discordant with in vitro susceptibilities. This practice was prevalent and similar across hospital types. Bacteremic patients who received in vitro-discordant empiric therapy displayed a higher mortality risk than recipients of concordant therapy. S. aureus and Enterobacterales and their resistance phenotypes account for the overwhelming majority of burden and impact of in vitro-discordant therapy, warranting development and wide implementation of effective rapid point-of-care diagnostics, especially those targeting these pathogens and their resistance phenotypes. In collaboration with the investigators at the Harvard Department of Population Medicine, we used larger electronic health record data from over a hundred U.S. hospitals and determined that despite the extensive use of broad-spectrum empiric antibiotic therapy for community-onset sepsis, the prevalence of antibiotic resistant pathogens warranting such therapy is small. Rapid diagnostics targeting resistance phenotypes may have a role in enhancing antibiotic stewardship in sepsis.